A Cure for Sickle Cell Exists. Getting It Is the Hard Part.

In December 2023, the Food and Drug Administration approved the first medicine of its kind: a one-time CRISPR gene-editing therapy for sickle cell disease, a painful, inherited blood disorder that has had almost nothing in the way of new options for decades. For the people who live with it, the word that gets used is not "treatment." It is "cure."

And yet, in all of 2025, only 111 people began the infusion process in the United States (Vertex Pharmaceuticals fourth-quarter results, reported by BioSpace). For a disease that affects roughly 100,000 Americans, that is not a rounding error. It is the whole story.

Why so few? Not because the science failed. Because access is a separate problem from approval — and the two almost never arrive together.

The therapy costs in the range of two million dollars. It requires months of preparation, a hospital stay, and a specialized center that can perform it. And it has to be paid for by an insurer or a state Medicaid program that has never had to write a check quite like this one. When a single claim is that large, the approval process around it becomes its own gauntlet: benefit verifications, coverage determinations, outcomes agreements negotiated state by state.

Here is the part worth sitting with. The medicine was ready in 2023. The system to pay for it is still being built in 2026. This year, the federal government's Cell and Gene Therapy Access Model began bringing states and the manufacturer together to negotiate outcomes-based agreements — arrangements where payment is tied to whether the therapy actually works — specifically to widen Medicaid access for sickle cell patients (Centers for Medicare & Medicaid Services). It is a sensible fix. It is also arriving two years after the cure did.

What this means for you

Most people reading this will never need a two-million-dollar gene therapy. But the lesson underneath it is the one that touches nearly every patient: a treatment being approved, even celebrated, is not the same as a treatment you can get. The gap between "this exists" and "this is covered for you" is where patients get lost — whether the therapy costs two million dollars or two hundred.

That gap has a shape, and it is always the same: a coverage determination, a prior authorization, a denial, an appeal. The dollar figures change. The paperwork does not.

What you can do today

If you are facing a high-cost or specialty treatment and your coverage is unclear or denied, the steps are the same ones that move smaller claims:

Ask your insurer, in writing, for the specific reason behind any denial or delay. You are entitled to it.

Ask whether your plan has a coverage policy for the treatment, and request a copy. Knowing the criteria tells you what your appeal needs to say.

If you have been denied, appeal. A denial is a starting position, not a verdict.

Ellen can help you read a denial, find the policy behind it, and build the appeal — for any treatment, at any price. The cure is only half the fight. The other half is the paperwork, and that is the half you do not have to face alone.

Ellen does not provide medical advice. For treatment decisions, talk to your doctor.

Sources: Vertex Pharmaceuticals Q4 2025 results (via BioSpace); U.S. Food and Drug Administration; Centers for Medicare & Medicaid Services, Cell and Gene Therapy Access Model.